Published in Vaccine Weekly, April 6th, 2005
Pharmexa entered into an agreement with BN ImmunoTherapeutics, a subsidiary of Bavarian Nordic, whereby BN ImmunoTherapeutics obtains a worldwide nonexclusive license to formulate Pharmexa's HER-2 DNA AutoVac therapeutic vaccine technology against breast cancer in their MVA-BN vector. The new agreement amends the previous agreement between Pharmexa and Bavarian Nordic announced in October 2003.
Under the new agreement, BN...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.